These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37781383)

  • 1. Multi-omics segregate different transcriptomic impacts of anti-IL-17A blockade on type 17 T-cells and regulatory immune cells in psoriasis skin.
    Kim J; Lee J; Li X; Kunjravia N; Rambhia D; Cueto I; Kim K; Chaparala V; Ko Y; Garcet S; Zhou W; Cao J; Krueger JG
    Front Immunol; 2023; 14():1250504. PubMed ID: 37781383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell transcriptomics suggest distinct upstream drivers of IL-17A/F in hidradenitis versus psoriasis.
    Kim J; Lee J; Li X; Lee HS; Kim K; Chaparala V; Murphy W; Zhou W; Cao J; Lowes MA; Krueger JG
    J Allergy Clin Immunol; 2023 Sep; 152(3):656-666. PubMed ID: 37271319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The imbalance between Type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris.
    Kim J; Moreno A; Krueger JG
    Front Immunol; 2022; 13():1005115. PubMed ID: 36110854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pellino-1 promotes intrinsic activation of skin-resident IL-17A-producing T cells in psoriasis.
    Kim SH; Oh J; Roh WS; Park J; Chung KB; Lee GH; Lee YS; Kim JH; Lee HK; Lee H; Park CO; Kim DY; Lee MG; Kim TG
    J Allergy Clin Immunol; 2023 May; 151(5):1317-1328. PubMed ID: 36646143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
    Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
    J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets.
    Kim J; Lee J; Kim HJ; Kameyama N; Nazarian R; Der E; Cohen S; Guttman-Yassky E; Putterman C; Krueger JG
    J Allergy Clin Immunol; 2021 Nov; 148(5):1281-1292. PubMed ID: 33932468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα.
    Tittes J; Brell J; Fritz P; Jonak C; Stary G; Ressler JM; Künig S; Weninger W; Stöckl J
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):613-626. PubMed ID: 38459237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
    Xie XJ; Di TT; Wang Y; Wang MX; Meng YJ; Lin Y; Xu XL; Li P; Zhao JX
    Mol Immunol; 2018 Sep; 101():386-395. PubMed ID: 30064075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.
    Russell CB; Rand H; Bigler J; Kerkof K; Timour M; Bautista E; Krueger JG; Salinger DH; Welcher AA; Martin DA
    J Immunol; 2014 Apr; 192(8):3828-36. PubMed ID: 24646743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells.
    Zaba LC; Fuentes-Duculan J; Eungdamrong NJ; Abello MV; Novitskaya I; Pierson KC; Gonzalez J; Krueger JG; Lowes MA
    J Invest Dermatol; 2009 Jan; 129(1):79-88. PubMed ID: 18633443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
    Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
    Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages.
    Brunner PM; Koszik F; Reininger B; Kalb ML; Bauer W; Stingl G
    J Allergy Clin Immunol; 2013 Nov; 132(5):1184-1193.e8. PubMed ID: 23890755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis.
    Lovato P; Norsgaard H; Tokura Y; Røpke MA
    J Dermatol Sci; 2016 Mar; 81(3):153-64. PubMed ID: 26794805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic Profiling of Peripheral Edge of Lesions to Elucidate the Pathogenesis of Psoriasis Vulgaris.
    Boonpethkaew S; Meephansan J; Jumlongpim O; Tangtanatakul P; Soonthornchai W; Wongpiyabovorn J; Vipanurat R; Komine M
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses.
    Mercurio L; Failla CM; Capriotti L; Scarponi C; Facchiano F; Morelli M; Rossi S; Pagnanelli G; Albanesi C; Cavani A; Madonna S
    PLoS One; 2020; 15(4):e0222969. PubMed ID: 32352958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
    Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
    J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response.
    Wu D; Hailer AA; Wang S; Yuan M; Chan J; El Kurdi A; Rahim M; Kondo A; Han D; Ali H; D'Angio B; Mayer A; Klufas D; Kim E; Shain AH; Choi J; Bhutani T; Simpson G; Grekin RC; Ricardo-Gonzalez R; Purdom E; North JP; Cheng JB; Cho RJ
    Sci Immunol; 2024 Jan; 9(91):eadi2848. PubMed ID: 38277466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation.
    Xu X; Prens E; Florencia E; Leenen P; Boon L; Asmawidjaja P; Mus AM; Lubberts E
    Front Immunol; 2021; 12():719562. PubMed ID: 34616394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
    Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
    J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A.
    Li Y; Golden JB; Camhi MI; Zhang X; Fritz Y; Diaconu D; Ivanco TL; Simon DI; Kikly K; McCormick TS; Wang Y; Ward NL
    J Invest Dermatol; 2018 Feb; 138(2):310-315. PubMed ID: 28951241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.